title: [Disseminated intravascular coagulation].
abstract: Disseminated intravascular coagulation is characterised by systemic activation of blood coagulation, resulting in formation of intravascular thrombi and impaired organ perfusion. Simultaneously, the ongoing consumption of platelets and coagulation factors may lead to bleeding. Disseminated intravascular coagulation is seen in septicaemic infections, trauma, malignancies, obstetrical complications, vascular diseases, toxic and immunological reactions. In summary, the systemic deposition of fibrin is caused by enhanced thrombin generation, simultaneous depression of physiological anticoagulant mechanisms and diminished fibrin degradation due to inhibition of fibrinolysis. The increased insight into the pathogenesis of disseminated intravascular coagulation provides a solid basis for development of improved management strategies for patients with this complication. Therapy may include anticoagulants, platelet and plasma transfusion, concentrates of coagulation inhibitors and antifibrinolytic agents.
authors.affiliation: Academisch Medisch Centrum/Universiteit van Amsterdam, afd. Inwendige Geneeskunde en afd. Intensive Care, Amsterdam.
authors.forename: M
authors.initials: M
authors.lastname: Levi
authors.forename: E
authors.initials: E
authors.lastname: de Jonge
authors.forename: H
authors.initials: H
authors.lastname: ten Cate
mesh_terms: D000925:Anticoagulants / Q000627:therapeutic use; D000933:Antifibrinolytic Agents / Q000627:therapeutic use; D001160:Arterioles / Q000473:pathology; D001706:Biopsy; D004211:Disseminated Intravascular Coagulation / Q000175:diagnosis / Q000209:etiology / Q000503:physiopathology / Q000628:therapy; D005342:Fibrinolysis; D006801:Humans; D007668:Kidney / Q000473:pathology; D010956:Plasmapheresis; D017713:Platelet Transfusion
chemical_list: D000925:Anticoagulants; D000933:Antifibrinolytic Agents